Abstract: The invention relates to method of preparing a viscoelastic therapeutic liquid comprising a viscoelastic agent and a homogenously distributed therapeutically active agent, wherein the therapeutically active agent is distributed throughout the viscoelastic compound when the viscoelastic compound is in dry form. In one embodiment of the invention, the viscoelastic compound in dry form is mixed with an aqueous solution of the therapeutically active agent. The invention further relates to utilities of homogenous viscoelastic compositions in therapeutic applications including ophthalmic surgery.

Abstract: The present invention relates to new substituted azetidine compounds of formula (I): or pharmaceutically acceptable salts thereof, as further described herein, to pharmaceutical compositions containing them, and the use of the compounds in the treatment of functional gastrointestinal disorders, IBS, and functional dyspepsia. The compounds are neurokinin (NK) antagonists. The present invention further relates to processes for the preparation of the compounds.

Abstract: Formulations and methods for protecting cell layers and tissues exposed to trauma are disclosed. Different molecular mass fractions of the same polymer can be used to better control the physical and chemical properties of the formulation. In this manner the benefits of both fractions, and not just the benefits of the average of the fractions, can be seen in the formulation.

Abstract: A system for providing an intraocular lens includes a processor and a computer readable memory. The computer readable memory is configured to communicate with the processor, the memory having stored therein at least one of: one or more ocular dimensions, and at least one predetermined refractive outcome. The memory further includes a sequence of instructions which, when executed by the processor, cause the processor to select an intraocular lens, select a power of an intraocular lens, or provide an intraocular lens. The sequence of instructions includes determining one or more dimensions of an eye. The instructions also include calculating, based on a mathematical relationship, a distance from an apex of a cornea of the eye to an apex or plane of the intraocular lens after insertion into the eye. The instructions further calculating an optical power of the intraocular lens suitable for providing a predetermined refractive outcome.

Abstract: A system for providing an intraocular lens includes a processor and a computer readable memory. The computer readable memory is configured to communicate with the processor, the memory having stored therein at least one of: one or more ocular dimensions, and at least one predetermined refractive outcome. The memory further includes a sequence of instructions which, when executed by the processor, cause the processor to select an intraocular lens, select a power of an intraocular lens, or provide an intraocular lens. The sequence of instructions includes determining one or more dimensions of an eye. The instructions also include calculating, based on a mathematical relationship, a distance from an apex of a cornea of the eye to an apex or plane of the intraocular lens after insertion into the eye. The instructions further calculating an optical power of the intraocular lens suitable for providing a predetermined refractive outcome.

Abstract: A system for providing an intraocular lens includes a processor and a computer readable memory. The computer readable memory is configured to communicate with the processor, the memory having stored therein at least one of: one or more ocular dimensions, and at least one predetermined refractive outcome. The memory further includes a sequence of instructions which, when executed by the processor, cause the processor to select an intraocular lens, select a power of an intraocular lens, or provide an intraocular lens. The sequence of instructions includes determining one or more dimensions of an eye. The instructions also include calculating, based on a mathematical relationship, a distance from an apex of a cornea of the eye to an apex or plane of the intraocular lens after insertion into the eye. The instructions further calculating an optical power of the intraocular lens suitable for providing a predetermined refractive outcome.

Abstract: The present invention relates to new azetidine compounds, to pharmaceutical compositions containing them and the use of said compounds in the treatment of functional gastrointestinal disorders, IBS and functional dyspepsia. The compounds are neurokinin (NK) antagonists. The present invention further relates to processes for the preparation of the compounds.

Abstract: A kit is provided, which comprises a) a collagen patch and b) an adhesive composition comprising (i) fibrin, fibrinogen or a combination thereof, and (ii) a biocompatible polymer capable of forming a viscous aqueous solution. Also provided is use of the kit for the preparation of a sealing device for use in ophthalmic surgery to replace a natural lens which has been removed, in which sealing device the collagen patch of the kit is adapted to seal an opening in a capsular bag of an eye while admitting the entrance of an injection device through the opening for injection of a lens-forming material into the capsule; and in which sealing device the adhesive composition of the kit is adapted to be applied to the collagen patch so as to enable adhesion of the collagen patch to the capsular bag. Also provided are methods for sealing an opening in a capsular bag of an eye, in which methods the kit is employed.

Abstract: A system for providing an intraocular lens includes a processor and a computer readable memory. The computer readable memory is configured to communicate with the processor, the memory having stored therein at least one of: one or more ocular dimensions, and at least one predetermined refractive outcome. The memory further includes a sequence of instructions which, when executed by the processor, cause the processor to select an intraocular lens, select a power of an intraocular lens, or provide an intraocular lens. The sequence of instructions includes determining one or more dimensions of an eye. The instructions also include calculating, based on a mathematical relationship, a distance from an apex of a cornea of the eye to an apex or plane of the intraocular lens after insertion into the eye. The instructions further calculating an optical power of the intraocular lens suitable for providing a predetermined refractive outcome.

Abstract: The present invention relates to a process for the preparation of quartenary ammoniumsalts of esomeprazole. Further, the present invention also relates to the use quartenary ammoniumsalts of esomeprazole for the treatment of gastrointestinal disorders, pharmaceutical compositions containing them as well as the quartenary ammoniumsalts of esomeprazole, as such.

Abstract: Formulations and methods for protecting cell layers and tissues exposed to trauma are disclosed. Different molecular mass fractions of the same polymer can be used to better control the physical and chemical properties of the formulation. In this manner the benefits of both fractions, and not just the benefits of the average of the fractions, can be seen in the formulation.

Abstract: The invention relates to method of preparing a viscoelastic therapeutic liquid comprising a viscoelastic agent and a homogenously distributed therapeutically active agent, wherein the therapeutically active agent is distributed throughout the viscoelastic compound when the viscoelastic compound is in dry form. In one embodiment of the invention, the viscoelastic compound in dry form is mixed with an aqueous solution of the therapeutically active agent. The invention further relates to utilities of homogenous viscoelastic compositions in therapeutic applications including ophthalmic surgery.

Abstract: A kit is provided, which comprises a) a collagen patch and b) an adhesive composition comprising (i) fibrin, fibrinogen or a combination thereof, and (ii) a biocompatible polymer capable of forming a viscous aqueous solution.

Abstract: The present invention relates to novel compounds of Formula I, and pharmaceutically acceptable salts thereof, as antibacterial agents. The compounds of the present invention are nitric oxide releasing derivatives of proton pump inhibitors (NO-releasing PPIs). In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above. The invention also relates to new intermediates for use in the preparation of the novel compounds. Additionally the present invention relates to co-administration of NO-releasing PPIs with other known medicaments.

Abstract: The present invention relates to novel compounds of Formula I, and pharmaceutically acceptable salts thereof, as antibacterial agents. The compounds of the present invention are nitric oxide releasing derivatives of proton pump inhibitors (NO-releasing PPIs). In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above. The invention also relates to new intermediates for use in the preparation of the novel compounds. Additionally the present invention relates to co-administration of NO-releasing PPIs with other known medicaments.

Abstract: The invention is related to a reflector lamp comprising a parabolic primary reflecting section, a parabolic or spheric secondary reflecting section joined to the primary reflecting section, and an incandescent or discharge light source. The secondary reflecting section has faceted surfaces which longitudinally extend along the surface thereof so that most or substantially all the light reflected by the faceted surfaces avoids the light source and thus the light, which would be absorbed or scattered by the light source, is minimized or substantially eliminated.

Abstract: Novel compounds of the formula ##STR1## pharmaceutical compositions containing such compounds as active ingredient, and the use of the compounds in medicine for treating gastric acid related diseases such as gastritis, gastric ulcer, duodenal ulcer and reflux esophagitis.